Industry
Biotechnology
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Loading...
Open
20.09
Mkt cap
1.5B
Volume
189K
High
20.28
P/E Ratio
-168.33
52-wk high
28.15
Low
19.94
Div yield
N/A
52-wk low
16.56
Portfolio Pulse from
November 12, 2024 | 9:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 2:57 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 5:53 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 11:32 am
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 8:01 pm
Portfolio Pulse from Benzinga Newsdesk
September 13, 2024 | 1:04 pm
Portfolio Pulse from Avi Kapoor
July 23, 2024 | 5:21 pm
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 4:55 pm
Portfolio Pulse from Avi Kapoor
July 23, 2024 | 3:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.